Neurocristopathy

This study tested a new RNA cancer vaccine in 119 people with advanced melanoma. The vaccine was designed to train the immune system to attack four proteins found on melanoma cells. The main goal was to check the vaccine's safety and find the best dose, while also looking for sig…

This phase 3 trial tested a personalized vaccine made from a patient's own immune cells and tumor RNA in 200 people with a high-risk form of eye cancer (uveal melanoma with monosomy 3). After surgery to remove the tumor, half received the vaccine over two years and half were simp…

This study tested a new type of vaccine made by fusing a patient's own immune cells with their cancer cells. The goal was to see if it was safe and could help the immune system fight advanced melanoma. Twenty adults with spreading melanoma that was getting worse took part. The va…

This study tested a personalized vaccine made from each patient's own melanoma mutations. The goal was to see if it is safe and possible to create such a vaccine. Fifteen people with advanced melanoma received the vaccine, and researchers checked for side effects and immune respo…

This early-stage trial tested a custom-made vaccine called WDVAX in 23 people with advanced melanoma. The vaccine is created from each patient's own killed tumor cells, mixed with immune-boosting proteins, and formed into a small dissolvable tablet. The goal was to see if it's sa…

This phase 2 pilot study tests whether adding the investigational drug vidutolimod to the immunotherapy nivolumab can destroy more melanoma tumors in lymph nodes or nearby skin areas before surgery. Participants have stage IIIB/C/D melanoma that has spread but not to distant orga…

This study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug is taken orally and works by blocking the action of the altered gene. The main goal was to see how many patients had their tumors shrink or dis…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This completed phase 2 trial tested whether adding alpha interferon to standard surgery helps prevent skin melanoma from returning. 278 participants with stage I-IV melanoma were assigned to one of six groups, including surgery alone, low or high dose interferon, chemotherapy, or…

This study tests a 5-week community-based program that teaches protective behavioral strategies to reduce alcohol use in men aged 35–44 with hazardous drinking habits in rural Vietnam. Participants learn to set safe drinking limits, choose nonalcoholic drinks, and plan ahead, wit…

This phase II trial tests whether giving two targeted drugs (dabrafenib and trametinib) before and after surgery can improve outcomes for people with stage IIIB-C melanoma that has a BRAF V600 mutation. 35 participants will take the drugs for 12 weeks before surgery, then continu…

This study tested a new approach for people with advanced melanoma that can be surgically removed. Participants received a combination of two immunotherapies: one injected directly into the tumor (Tavo) and one given through a vein (nivolumab). After 12 weeks, they had surgery to…

This study tested the safety of combining two drugs, alpelisib and fulvestrant, in 40 men and post-menopausal women with a certain type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that had worsened after hormone therapy. The goal was to track side effects. The …

This phase 3 trial tested whether a yeast-derived immune stimulant (GM-CSF) and a peptide vaccine, alone or together, could prevent melanoma from returning after surgery. 815 patients with no visible cancer after complete surgical removal of advanced melanoma were randomly assign…

This phase 3 trial tested the safety of giving a monoclonal antibody (dinutuximab) along with immune-boosting drugs and a vitamin-like drug to children with high-risk neuroblastoma after a stem cell transplant. The goal was to see if this combination could be given safely and hel…

This large study tested whether evolocumab (Repatha), a cholesterol-lowering injection, could reduce major cardiovascular events like heart attacks, strokes, or death in over 12,000 adults at high risk but without a prior heart attack or stroke. Participants received either evolo…

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This study tested the drug nivolumab in 26 people with stage IIB or IIC melanoma that had been completely removed by surgery. The goal was to see if nivolumab, an immunotherapy that helps the immune system attack cancer cells, could prevent the melanoma from coming back. Particip…

This study offers ongoing treatment with alectinib or crizotinib to about 200 adults with ALK- or RET-positive cancer who were already benefiting from these drugs in a previous Roche trial. The main goal is to monitor safety and side effects as patients continue therapy after the…

This early-phase study tested an experimental drug called APX005M added to two standard immunotherapies (nivolumab and ipilimumab) in 26 people with advanced melanoma or kidney cancer who had not received prior immune therapy. The main goals were to check safety and find the best…

This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. Th…

This study tested a new approach for stage IIIB/C melanoma, the deadliest form of skin cancer. Nineteen participants received a single infusion of the immunotherapy drug nivolumab, followed by cryotherapy (freezing) of a cancerous lymph node, and then an injection of another immu…

This study tested whether N-acetylcysteine (NAC), an antioxidant drug, can improve motor skills and learning in children with neurofibromatosis type 1 (NF1). Twenty-five children aged 8 to 16 took NAC or a placebo for 8 weeks. The goal was to see if NAC is safe and helps with mov…

This Phase 2 trial tested whether adding bosentan, a drug used for blood vessel conditions, to standard chemotherapy (dacarbazine) could slow tumor growth in people with stage IV melanoma. The study enrolled 80 adults with advanced melanoma and compared the combination to chemoth…

This study tested a combination of two drugs, sitravatinib (a pill) and tislelizumab (an IV infusion), in 16 people with a rare eye cancer (uveal melanoma) that had spread to the liver. The goal was to see if the combo could shrink liver tumors better than current treatments. Par…

This study tested whether adding two immunotherapy drugs (dinutuximab and GM-CSF) to standard chemotherapy is safe and doable for children newly diagnosed with high-risk neuroblastoma. Forty-two children took part. The goal was to see if the extra drugs cause too many side effect…

This study tested a drug called indoximod, taken as a pill, together with standard immune checkpoint inhibitors (ipilimumab or pembrolizumab) in 131 adults with advanced or metastatic melanoma that could not be removed by surgery. The goal was to see if the combination was safe a…

This study looked at 216 people with advanced melanoma that had stopped responding to standard treatments. Researchers tested each person's tumor for specific genetic changes and then gave them a drug designed to target that change. The goal was to see if this personalized approa…

This study tested whether adding other treatments to the drug pembrolizumab can help people with advanced melanoma that hasn't been treated before. Researchers checked safety and how many people's tumors shrank or disappeared. The trial involved 335 participants and was part of a…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This phase 2 trial tested two drugs, selumetinib and sirolimus, in 21 people with advanced malignant peripheral nerve sheath tumors (MPNST), a rare cancer often linked to neurofibromatosis type 1. The goal was to see if the combination could shrink or stabilize tumors. The study …

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This early-phase study tested a single dose of an experimental antibody (MEDI0562) given before surgery to 13 patients with advanced head and neck cancer or melanoma. The goal was to see if the drug safely activates the immune system to fight the cancer. Researchers compared givi…

This early-phase trial tested whether giving activated natural killer (NK) cells, with or without a protein called rhIL15, is safe and feasible for children and young adults with solid tumors that didn't respond to other treatments. Sixteen participants received chemotherapy to l…

This early-stage study tested a new drug called LBL-007 combined with two other medicines (toripalimab and axitinib) in 79 people with advanced melanoma that could not be removed by surgery or had spread. The main goals were to check safety and find the best dose. Researchers als…

This phase II trial tested whether adding stereotactic body radiation therapy (SBRT) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Nine patients with metastatic disea…

This study tested the drug sunitinib (Sutent) in 71 people with advanced thyroid cancer that had spread or could not be removed by surgery. The goal was to see if the drug could shrink tumors when standard treatments like radioactive iodine no longer work. Participants took sunit…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This study tested whether adding the drug bevacizumab (Avastin) to standard chemotherapy helps children with neuroblastoma that has returned or not responded to treatment. The trial enrolled 225 children aged 1 to 21. Researchers looked at tumor shrinkage and how long the disease…

This early-stage study tested a custom-made yeast vaccine designed to train the immune system to recognize and attack leftover cancer cells. Five adults with various cancers (like colorectal, breast, or lung) who had completed initial treatment received the vaccine. The goal was …

This Phase 2 trial tested a combination of targeted drugs (vemurafenib and cobimetinib) and immunotherapy (atezolizumab and tiragolumab) given before surgery to 64 patients with high-risk stage III melanoma. The goal was to see if the treatment could eliminate or shrink the cance…

This phase 2 trial tested whether a reduced dose of chemotherapy drugs (fludarabine and cyclophosphamide) given before infusing a patient's own tumor-fighting immune cells (lifileucel) could work for advanced melanoma that has spread or can't be removed. Eleven adults with stage …

This study compared two surgical techniques for treating Hirschsprung's disease in children: the traditional Soave method and a newer heart-shaped anastomosis. The trial involved 177 children under 14 years old across multiple hospitals. The goal was to see which approach leads t…

This phase 2 trial tested a combination of a radioactive drug (MIBG), intensive chemotherapy, and a stem cell transplant in 50 children with relapsed or hard-to-treat neuroblastoma. The goal was to see if this approach could shrink tumors and improve survival. The treatment aims …

This early-stage trial tested a radioactive drug called 177Lu-DOTATATE in one child with neuroblastoma that had come back or not responded to standard treatments. The drug targets tumor cells that have a specific marker (somatostatin receptors). The goal was to find a safe dose. …

This study tested a special skin graft called X A-DERM™ mADM in 16 people who had Mohs surgery to remove skin cancers like basal cell carcinoma or squamous cell carcinoma. The graft has a micro-textured surface designed to help the wound heal faster and leave a better scar. Resea…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This study tested whether taking two targeted drugs (dabrafenib and trametinib) for 12 months after melanoma surgery could keep the cancer from returning. It included 870 adults with high-risk stage III melanoma that had a specific BRAF V600 mutation. Results showed the drug comb…

This phase 2 trial tested the drug darovasertib in 15 people with high-risk uveal melanoma (a rare eye cancer) who were scheduled for eye removal surgery. Participants took the drug for up to 4 weeks before surgery, and some continued for 6 months afterward. The main goals were t…

This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients w…

This early-phase study tested a combination of three oral drugs (irinotecan, temozolomide, and cefixime) in 30 children whose high-risk neuroblastoma had come back or not responded to standard treatment. The goal was to find the safest dose of irinotecan when given with the other…

This early-phase study tested an intravenous form of the drug fenretinide in 17 children whose neuroblastoma had come back or didn't respond to standard treatments. The main goals were to find the safest dose and understand side effects. Researchers also looked at how the drug mo…

This early-phase study tested a new approach for children with neuroblastoma that did not respond to standard treatments. It used two rapid infusions of a radioactive drug (I-MIBG) to target cancer cells, followed by a stem cell transplant to restore healthy blood cells. The goal…

This study tested a new antibody (hu14.18K322A) added to standard chemotherapy for 153 children with high-risk neuroblastoma, a serious nerve tissue cancer. The goal was to see if the combination improves tumor shrinkage and delays the cancer from coming back. While the treatment…

This early-phase study tested a combination of two chemotherapy drugs (irinotecan and vincristine) plus a radioactive drug (131I-MIBG) in 26 children with high-risk neuroblastoma that had come back or not responded to standard treatment. The goal was to find the safest dose of th…

This early-stage trial tested a new oral form of the chemotherapy drug fenretinide in 80 children whose neuroblastoma had come back or resisted standard treatment. The goal was to find the safest dose and understand side effects. Researchers also looked at how the body processes …

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…

This early-phase trial tested the safety of combining two drugs—L-NMMA and pembrolizumab (Keytruda)—in 12 adults with various advanced cancers. Pembrolizumab helps the immune system recognize cancer cells, while L-NMMA may remove a chemical barrier that blocks immune attack. The …

This early study tested whether giving a single dose of nivolumab with either ipilimumab or relatlimab before surgery is safe and possible for people with melanoma that has spread to the brain. Only one person took part, so results are very limited. The goal was to see how the dr…

This phase 2 study tested a combination of oral azacitidine (a chemotherapy-like drug) and pembrolizumab (an immunotherapy) in 24 people with advanced melanoma that had spread. The goal was to see if the combo could shrink tumors or slow the disease, both in patients who had neve…

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…

This study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…

This early-phase trial tested a new personalized therapy called TBio-4101 for people with advanced melanoma that had stopped responding to standard treatments. The therapy uses a patient's own tumor-fighting immune cells, which are collected, multiplied in the lab, and then infus…

This pilot study tested whether metformin, a common diabetes drug, could help treat advanced melanoma that had spread and stopped responding to other treatments. Twenty adults with stage IIIC or IV melanoma took metformin to see if it could shrink their tumors. The goal was to fi…

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This early-phase study tested whether adding a TNF-blocking drug (infliximab or certolizumab) to standard immunotherapy (nivolumab and ipilimumab) is safe for people with advanced melanoma that has spread. The main goal was to find the best dose and check for serious side effects…

This study tested whether adding denosumab (a bone-strengthening drug) to standard immunotherapy (pembrolizumab or nivolumab) could help control advanced melanoma that has spread. Researchers enrolled 25 adults with stage III or IV melanoma who had not received prior immunotherap…

This phase 3 trial tested whether ABP 206, a biosimilar to the cancer drug nivolumab (Opdivo), works similarly in people with advanced melanoma that has been surgically removed. 256 participants received either ABP 206 or Opdivo every 4 weeks for a year. The goal was to see if th…

This phase 2 trial tested a personalized cell therapy called lifileucel for people with advanced melanoma that had spread and stopped responding to standard treatments. Researchers took immune cells from each patient's tumor, multiplied them in a lab, and infused them back after …

This study tested a gel called Picato (ingenol mebutate) on 20 people with a very early form of melanoma on the face, called lentigo maligna. Participants applied the gel once a day for three days. The goal was to see if the gel could make the cancer disappear completely, offerin…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This study tested a new drug called IMCgp100 in 378 adults with a specific genetic type (HLA-A*0201) of advanced uveal melanoma, a rare eye cancer. Participants received either IMCgp100 or one of three standard treatments (dacarbazine, ipilimumab, or pembrolizumab). The main goal…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This early-phase study tested whether combining a topical cream (imiquimod) with an immunotherapy drug (pembrolizumab) is safe and effective for people with advanced melanoma that has spread. Seven participants with stage IIIB to IV melanoma were enrolled. The goal was to see if …

This study tested whether combining two drugs, brentuximab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma, lung cancer, or head and neck cancer that has spread. About 161 adults took part. The main goal was to see how many patients had their tumors …

This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…

This early study tested combining the immunotherapy drug pembrolizumab with precise radiation (stereotactic radiosurgery) in 25 people with melanoma or lung cancer that had spread to the brain. The main goal was to check for serious side effects. Researchers also tracked how long…

This study tested whether adding an immunotherapy drug (dinutuximab) and immune-boosting medicines to standard treatment helps children with high-risk neuroblastoma stay cancer-free longer. About 1,400 children who had already received intensive chemotherapy and a stem cell trans…

This early-stage trial tested a personalized vaccine made from a patient's own immune cells and tumor material for people with metastatic uveal melanoma, a rare eye cancer that has spread. The vaccine was added to standard treatments like immunotherapy or chemotherapy. The main g…

This study tested an experimental drug called ENV-101 (taladegib) in 20 adults with advanced solid tumors that have a specific genetic mutation (PTCH1 loss-of-function). The drug works by blocking a growth pathway in cancer cells. Researchers measured how many patients' tumors sh…

This study tested the safety and effectiveness of the drug abemaciclib combined with other cancer medicines in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if th…

This phase 3 trial tested a combination of two targeted drugs, LGX818 and MEK162, against standard treatments in 921 people with advanced melanoma that has a BRAF V600 mutation. The study compared the combo to vemurafenib alone or LGX818 alone to see which worked better at delayi…

This early-phase trial tested a combination of two oral drugs, trametinib and ceritinib, in 27 people with advanced melanoma that had stopped responding to prior treatments. The main goals were to find a safe dose and see if the combination could shrink tumors. The study is compl…

This study tested a drug called TOUR006 in 143 adults with chronic kidney disease and high levels of a protein linked to inflammation (hs-CRP). The goal was to see if monthly or quarterly shots could safely lower inflammation. The study is complete, and results will show if the d…

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This phase II trial tested a powerful combination for people with advanced melanoma that has spread. The approach uses a targeted drug (vemurafenib), immune cells grown from the patient's own tumor (TIL), and high-dose IL-2 to boost the immune system. The study enrolled 17 partic…

This study tested the drug sorafenib (Nexavar) in 32 adults with uveal melanoma that had spread to other parts of the body. The goal was to see if the drug could stop tumors from growing for at least 24 weeks. Sorafenib is already used for other cancers, and researchers wanted to…

This phase 2 trial tested a gel called NFX-179 on skin tumors in 199 adults with neurofibromatosis type 1. Participants applied the gel daily for 26 weeks. The study measured safety and whether tumors shrank in size or height. Results suggest the gel may help reduce tumor volume,…

This study looked at 20 children with Hirschsprung disease, a condition where part of the bowel lacks nerve cells, causing severe constipation. Researchers compared two surgical methods—Swenson and Soave—to see which one had shorter operation time and better daily bowel movements…

This study tested whether a combination of two drugs, nivolumab and relatlimab, can shrink tumors in people with metastatic uveal melanoma, a rare eye cancer that has spread. Twenty-seven participants received the treatment to see how many responded. The goal was to control the d…

This early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…

This phase 2 trial tested whether giving the chemotherapy drug dacarbazine (DTIC) before re-trying immunotherapy could help patients with advanced melanoma whose cancer had stopped responding to immunotherapy. The study enrolled 38 adults with metastatic melanoma that had progres…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated yet. About 674 adults with stage III or IV melanoma took part. The goal was to see if the combination helps people live lo…

This study tested a new way to do stem cell transplants in 23 children with cancers that came back or didn't respond to treatment. The method removes certain immune cells from the donor's stem cells to help the child's body recover faster and fight infections better. The goal was…

This study tested two different doses of an experimental drug called RO7247669 in 93 people with advanced melanoma that had not been treated before. The goal was to see how well the drug controls the cancer and to find the best dose with the fewest side effects. Participants rece…

This early-phase study tested whether genetically modified T-cells (MAGE-A10ᶜ⁷⁹⁶T) are safe for people with advanced urothelial cancer, melanoma, or head and neck cancer. Ten participants received their own engineered immune cells after chemotherapy. The main goal was to check fo…

This study tested whether adding a personalized cancer vaccine (RO7198457) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated before. The trial involved 131 participants and measured how long th…

This early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…

This study tested a very strong treatment plan for children newly diagnosed with high-risk neuroblastoma, a serious nerve cell cancer. The approach combined intensive chemotherapy, a radioactive drug called 131I-MIBG, and a stem cell transplant to try to kill more cancer cells. T…

This early-phase study tested a new drug called IN10018, alone or with other medicines, in 51 adults with advanced melanoma that had spread. The main goal was to check safety and how the body handles the drug. The study included people with two hard-to-treat types of melanoma: uv…

This early-stage study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific KIT gene mutation and cannot be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. While some patients had their tu…

This study tested a combination of two immunotherapy drugs, low-dose ipilimumab and pembrolizumab, in 24 people with advanced melanoma that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors and improve survival. Participants receiv…

This phase 2 trial tested a combination of an experimental cancer vaccine (BNT111) and an immunotherapy drug (cemiplimab) in 184 adults with advanced melanoma that no longer responded to standard immunotherapy. Participants were randomly assigned to receive the combination or eit…

This early-phase study tested a combination of two experimental drugs (BGB-283 and PD-0325901) in 91 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if the drugs could shrink tumors. The trial is no…

This study tested a new treatment for children with high-risk neuroblastoma, a type of cancer. Researchers took the patients' own immune cells (T cells) and modified them to recognize and attack the cancer. Some of these cells were also trained to fight a common virus (EBV) to he…

This trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…

This study tested a new antibody called ICT01 combined with low-dose interleukin-2 (IL-2) in 56 people with advanced solid tumors like colorectal, ovarian, and pancreatic cancer. The goal was to see if the combo is safe and can shrink tumors. Early results suggest it may help con…

This study tested whether adding lenvatinib to pembrolizumab works better than pembrolizumab alone for people with advanced melanoma who haven't had prior treatment. It involved 131 Chinese participants with stage III or IV melanoma that could not be removed by surgery. The goal …

This early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…

This trial tested a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. The study enrolled 18 partici…

This study tested a new way to treat metastatic melanoma by using a patient's own immune cells. Doctors removed a tumor, grew special immune cells (TILs) from it in a lab, then gave them back to the patient along with high-dose IL-2. Before the cell infusion, patients received st…

This study tested an experimental treatment for metastatic melanoma using a patient's own immune cells (tumor-infiltrating lymphocytes) grown in a lab and given back along with high-dose IL-2. Before the cell infusion, all patients received chemotherapy to suppress their immune s…

This pilot study tested a new combination treatment for people with advanced melanoma that has spread. It combined a patient's own immune cells grown in a lab (called TILs) with an immunotherapy drug called ipilimumab. The main goals were to see if the treatment was safe and poss…

This phase II trial tested whether adding bevacizumab to the immunotherapy drug ipilimumab helps people with advanced melanoma that cannot be removed by surgery. The study enrolled 169 participants and measured overall survival and tumor progression. The goal was to see if the co…

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…

This early-phase trial tested a personalized immunotherapy for people with advanced solid tumors. Doctors removed a sample of each patient's tumor, grew the immune cells (TILs) in a lab, and then infused them back along with another drug. The goal was to see if this approach is s…

This early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab (Keytruda) in 6 people with advanced head and neck cancer, melanoma, or triple-negative breast cancer. The main goal was to check safety and side …

This phase 2 trial tested a combination of two drugs—BO-112, injected directly into tumors, and pembrolizumab, given through a vein—in 42 adults with advanced melanoma that had stopped responding to standard immunotherapy. The goal was to see if the combo could shrink tumors and …

This early-phase trial tested a new way to treat advanced cancers that have spread. It combined a special type of radiation with two immunotherapy drugs (MEDI4736 and tremelimumab) to see if the combination is safe and tolerable. The study included 53 adults with advanced melanom…

This early-stage trial tested a new drug called CFT1946, alone or with other drugs, in 89 adults with solid tumors that have a BRAF V600 mutation, including melanoma, lung, colon, and thyroid cancers. The main goals were to check safety and find the best dose. The study is comple…

This phase 2 trial tested a combination of an injected drug (LTX-315) and an intravenous immunotherapy (pembrolizumab) in 23 people with advanced melanoma that no longer responded to standard PD-1/PD-L1 inhibitors. The goal was to see if the combination could shrink tumors or slo…

This study tested a treatment for uveal melanoma that has spread to the liver. Tiny radioactive beads were injected into the liver's blood vessels to deliver radiation directly to tumors. The goal was to shrink or control the liver tumors. 48 patients took part, and the study loo…

This study tested giving the cancer drug nivolumab as a shot under the skin (instead of through an IV) to people with advanced cancers like lung, kidney, melanoma, liver, and colorectal cancer. The main goal was to see how the drug moves in the body and to check for side effects.…

This study tested an experimental drug called BDB001 in people with advanced solid tumors (like skin, lung, or kidney cancer) that had stopped responding to standard immunotherapy. The goal was to see if BDB001 could shrink tumors or slow their growth. Only one person took part, …

This early-phase trial tested a new drug called INCA32459 in 46 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see how the body handles the drug. It is too early to know if the drug works, but the results will guide fut…

This study tested whether a daily oral pill can safely and temporarily lower sperm counts in healthy men to prevent pregnancy. Ninety-two men took either the experimental drug (DMAU) alone, DMAU plus another hormone (LNG), or a placebo for 12 weeks. The goal was to see if sperm c…

This study tested a smartphone app to help young adult cancer survivors (ages 18-39) lose weight. The app tracked diet and activity as part of a behavioral weight loss program. The goal was to see if this approach was practical and well-liked by participants. The study involved 6…

This study tested several combinations of the immunotherapy drug pembrolizumab (Keytruda) with other experimental drugs in people with stage III melanoma that can be surgically removed. The goal was to see if these combinations are safe and more effective than current treatments …

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This early-phase trial tested a new approach for people with advanced melanoma that cannot be removed by surgery. The treatment combines a gene therapy injected directly into tumors with an oral drug that activates the therapy. The goal was to see if the combination is safe and t…

This completed phase 1/2 trial tested the safety and effectiveness of pembrolizumab (Keytruda) alone or combined with other drugs (quavonlimab or lenvatinib) in 56 people with melanoma that had spread to the brain. Participants had not received steroids recently and were neurolog…

This study tested a new drug called E7386 combined with the immunotherapy pembrolizumab (Keytruda) in 89 people with advanced melanoma, colorectal cancer, or liver cancer. The goal was to see if the combination is safe and can shrink tumors. Some participants with liver cancer al…

This phase 2 trial tested a drug called Taxoprexin (DHA-paclitaxel) in 22 people with metastatic uveal melanoma, a rare eye cancer that has spread. The drug was given weekly for 5 weeks in a 6-week cycle. The main goal was to see if tumors shrank or disappeared, and to check safe…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This study tested whether adding an immunotherapy drug (Hu3F8) plus GM-CSF to standard treatment could help children with high-risk neuroblastoma stay in remission longer. Fifty-nine children who had already achieved remission after initial therapy received the combination along …

This study tested a drug called MEK162 in 105 children with low-grade gliomas or other tumors that have a specific overactive growth signal. The goal was to find the best dose, check for side effects, and see if the drug could shrink tumors. Children took the drug by mouth twice …

This study tested two daily doses (150mg vs 300mg) of the drug vandetanib in 81 adults with advanced medullary thyroid cancer that had spread or caused symptoms. The goal was to see which dose better shrinks tumors and how side effects compare. Patients took the drug for up to 24…

This study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could s…

This early-phase trial tested a reduced dose of radiation in 78 children with high-risk neuroblastoma. The goal was to see if a lower dose could still control the tumor while causing fewer long-term side effects. Researchers monitored local control rates and side effects over tim…

This study compared two types of laparoscopic surgery (Swenson-like and Soave) for children with Hirschsprung disease, a condition where nerve cells are missing in part of the colon. Forty children were treated at Al-Azhar University Hospitals, and researchers measured bowel func…

This phase 3 trial tested a daily oral drug called vandetanib (ZD6474) against a placebo in 331 people with advanced medullary thyroid cancer that could not be removed by surgery. The main goal was to see if the drug could delay tumor growth. Researchers also measured how many pa…

This study tested a weekly injection of a new chemotherapy drug called Taxoprexin in 30 people with advanced melanoma that had spread to other parts of the body. The goal was to see if the drug could shrink tumors and how long that effect might last. Researchers also monitored si…

This early-phase trial tested whether it is safe and feasible to give patients their own immune cells (called tumor infiltrating lymphocytes, or TIL) directly into the liver artery. Eight adults with melanoma that had spread to the liver received the TIL infusion along with chemo…

This Phase 2 trial tested a modified polio virus called lerapolturev, alone or combined with an immunotherapy drug, in 27 adults with advanced melanoma that had stopped responding to standard PD-1 therapy. The virus was injected directly into tumors to trigger an immune attack. R…

This early-stage trial tested a drug called lorlatinib in 65 children and young adults with a type of nerve cancer (neuroblastoma) that had come back or not responded to treatment. The drug targets a specific genetic change (ALK) found in their tumors. The study looked at safety,…

This study tested whether a mobile game could help children aged 11-14 with chronic kidney failure better manage their condition. 68 children were split into two groups: one used the game, the other received standard education. Researchers measured changes in BMI, blood pressure,…

This study tested two ways to stimulate sacral nerves in 48 children aged 2-17 with severe constipation and fecal incontinence that didn't improve with standard care. One group got an implanted nerve stimulator, the other a non-invasive patch. The goal was to see if either approa…

This study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to…

This study tested whether a special PET scan (called 18F-DOPA PET-CT) can find brain metastases as well as or better than standard MRI in people with lung cancer, breast cancer, or melanoma. 32 adults with untreated brain metastases took part. The goal was to see if this PET meth…

This study tested whether an artificial intelligence (AI) system can help detect melanoma, a dangerous form of skin cancer. Researchers took photos of suspicious skin spots from 105 adults using a smartphone camera and let the AI analyze them. They compared the AI's results to di…

This completed study tested whether an AI device could help 16 doctors (10 general practitioners and 6 dermatologists) more accurately diagnose 13 different skin conditions, including melanoma, psoriasis, and acne. The doctors reviewed 29 medical images, first giving a diagnosis …

This study tested whether an artificial intelligence (AI) tool could help primary care doctors diagnose skin conditions more accurately. Nine doctors reviewed 30 images of various skin problems, first giving their own diagnosis and then a final diagnosis after seeing the AI's sug…

This study looked at whether a new blood marker called EM66 can help doctors tell the difference between high blood pressure caused by rare adrenal tumors (pheochromocytoma or paraganglioma) and regular high blood pressure. Researchers measured EM66 levels in 60 adults with eithe…

This study looked at whether a device called Nevisense, which measures the electrical properties of moles, can help doctors better assess suspicious moles during routine skin checks. Forty adults with many moles (at least 100) and several large moles took part. The goal is to imp…

This study tested a new type of microscope called SECM to see if it can take clear pictures of pigmented skin lesions like moles. Sixteen healthy adults with moles on their forearms had their skin imaged with both a standard dermatoscope and the SECM device. The goal was simply t…

This study looked at whether a special PET scan (18FDG dual-point) can tell the difference between real tumor growth and harmless inflammation caused by immunotherapy. Researchers studied 100 people with advanced lung cancer or melanoma who were being treated with drugs like nivo…

This study tests a program called FLARE that teaches families how to protect children from the sun. It includes children ages 8 to 17 who have a parent who survived melanoma and who have had at least one sunburn in the past year. Families are randomly assigned to either the FLARE…

This pilot study tested a virtual program designed to help older men at high risk for fractures reduce their risk of falls and broken bones. The program included personalized exercise plans delivered through a smartphone app and virtual nutrition counseling. Researchers enrolled …

This completed study tested a school-based educational program to improve sun protection among 38 rural Utah high school students. The program included a 90-minute session with skin cancer education, a risk self-assessment, and creating a personal sun protection plan. Surveys mea…

This study looked at whether giving people personalized information about their genetic risk for melanoma could encourage them to protect themselves from the sun. Over 2,000 adults received either standard sun safety tips or tailored advice based on their DNA. Researchers then tr…

This study tested two 8-week stress management programs delivered via secure video calls for 196 adolescents aged 12–17 with neurofibromatosis (NF1 or NF2). The goal was to see if these programs could improve emotional, social, and physical quality of life. Both programs taught c…

This study compared two therapies—myofeedback and neuromuscular electrical stimulation—to see which better improves arm and hand function in children aged 6 to 14 who have one-sided weakness (hemiplegia) after brain tumor surgery. Forty-five children participated, and researchers…

This study looked at whether aerobic exercise and virtual reality games could improve functional capacity, activity, and participation in children aged 6-10 living in care facilities. Sixty-three children were split into groups: one did aerobic exercise, one played VR games, and …

This study tested Emotional Freedom Techniques (EFT), a therapy that combines talking with gentle tapping on acupressure points, in 56 people who had been treated for melanoma and were in remission. The goal was to see if EFT could reduce fear of the cancer coming back and improv…

This study tested whether N-acetylcysteine (NAC), an over-the-counter antioxidant, could improve learning and motor skills in children with neurofibromatosis type 1 (NF1). Five children aged 8 to 16 took NAC or a placebo to see if it helped with movement and attention problems. T…

This completed phase 3 trial tested whether a patient outreach program—regular phone calls every two weeks—could help people with advanced medullary thyroid cancer spend less time experiencing moderate-to-severe side effects from the drug vandetanib. The study enrolled 205 adults…

This study tested a gel called ZYN002, applied to the skin, in 20 children and teens (ages 4-17) with 22q11.2 deletion syndrome. The main goal was to see if the gel is safe and tolerable over 38 weeks. Researchers also looked at whether it could improve behavior and other symptom…

This study looked at whether using finger puppets, video games, or stress balls can help reduce fear and improve emotional behavior in children aged 4-6 who need inhaler therapy. 120 children participated, and researchers measured their fear levels, emotional responses, and paren…

This study tested whether breathing in lavender essential oil for 15 minutes before skin cancer surgery could reduce anxiety. Sixty-six adults with early-stage melanoma or other skin cancers took part. Researchers measured anxiety using questionnaires and vital signs like heart r…

This study measured anxiety in 100 patients undergoing Mohs surgery for skin cancer. Researchers compared anxiety levels between first-time and returning patients, and also tested whether reading a short story about a typical patient's experience helped reduce anxiety. The goal i…

This study tested two stress and symptom management programs for adults with neurofibromatosis (NF1, NF2, or schwannomatosis). The programs were delivered through live videoconferencing over 8 weekly sessions. Researchers measured changes in quality of life and emotional well-bei…

This study gave a radioactive drug called 131I-MIBG to 15 people with advanced nerve tumors (neuroblastoma or pheochromocytoma) that had stopped responding to standard treatments. The goal was to see if it could ease symptoms and shrink tumors, while tracking side effects. Partic…

This early-phase study tested a single dexamethasone implant (Ozurdex) in 10 people with uveal melanoma who had fluid buildup under the retina after radiation treatment. The goal was to see if the implant is safe and can help reduce the fluid to prevent vision loss. The implant i…

This study tested whether cooling the skin before or during laser and injection treatments for neurofibromatosis type 1 (NF1) skin bumps can reduce pain. Thirteen adults with NF1 received four different treatments (two lasers and two injections) on both cooled and non-cooled skin…

This study looked at whether children with year-round allergic rhinitis can use a nasal steroid spray only when symptoms bother them, instead of every day. Sixty-eight children aged 6 to 18 were randomly assigned to either daily use or as-needed use of fluticasone furoate spray. …

This study tested a therapy called Managing Cancer and Living Meaningfully (CALM) to see if it helps people with brain cancer feel less distressed. 60 adults with brain tumors or brain metastases who had high depression or death anxiety took part. The study measured how many peop…

This study tested a program called CONTINUUM, where advanced cancer patients had a video visit with an oncology nurse within three days of leaving the hospital. The goal was to help patients feel more confident managing their health and improve communication with their care team.…

This study tested a new, smaller bowel irrigation device called Navina Mini in 27 children and teens aged 3 to 17 with bowel problems like severe constipation or leakage. The goal was to see if the device is safe, easy to use, and improves bowel emptying and satisfaction. Results…

This study looked at whether starting supportive care early, alongside standard cancer treatment, helps patients with metastatic uveal melanoma feel more supported. 162 adults with advanced eye cancer that had spread were randomly assigned to get either standard oncology visits o…

This study looks at rare genetic disorders where the body can't make cholesterol properly, which can cause birth defects and learning problems. Researchers collect blood, urine, and tissue samples from affected people and their families to learn more about these conditions. The g…

This study followed 17 adults with neurofibromatosis type 1 (NF1) over two years to learn how their skin tumors (dermal neurofibromas) grow and change. Researchers used special cameras and skin biopsies to measure tumor growth and look for genes that might influence it. The goal …

This study looked at people with neurofibromatosis type 1 (NF1) to better understand how harmless tumors (plexiform neurofibromas) turn into a rare cancer called MPNST. Ten participants had MRI, PET scans, and tumor biopsies. Researchers tested whether a special PET scan (FLT PET…

This study enrolled 500 skin cancer patients in China and analyzed over 1.2 million of their social media posts using artificial intelligence. The goal was to see if AI could detect signs of psychological distress and suicidal thoughts. Researchers hope this approach could lead t…

This completed study looked at 40,000 people with metastatic cancer who received the drug nivolumab. Researchers compared the old way of dosing (based on body weight) with a newer, simpler fixed dose. They used national health data to see if the fixed dose was just as good and mo…

This study brought together four expert skin pathologists to see how well they agree when diagnosing moles that might be melanoma. The goal was to create a reliable standard for future research. The experts reviewed images and discussed tricky cases to reach a consensus.

This study looks at people with neurofibromatosis type 1 (NF1) and their families to find out why some have more severe symptoms than others. Researchers will collect medical history, blood samples, and images to study genes and physical traits. The goal is to identify genes that…

This study examines the patient profiles and treatment patterns of adults with melanoma in Japan who were prescribed either dabrafenib with trametinib or encorafenib with binimetinib. Researchers are looking at data from 2012 to 2021 to understand patient characteristics and how …

This study explored whether lab-grown skin models containing a patient's own melanoma cells could predict which drug combinations would work best. Researchers took a small sample of a skin metastasis and used it to create 3D cultures and artificial skin. The goal was to test diff…

This study compared two methods for measuring bioavailable testosterone in the blood: the standard lab test (radioimmunoassay) and a mathematical calculation. Researchers included 270 men and women aged 18 to 90. The goal was to see if the calculation matches the lab test closely…

This study watched 152 melanoma patients who had their tumors surgically removed and then started nivolumab as part of their normal care. Researchers tracked how long patients stayed cancer-free, whether the cancer spread, and overall survival. The goal was to see how well the dr…

This completed study examined 127 melanoma patients to understand how the IL4I1 enzyme influences disease progression and resistance to treatments like immunotherapy and targeted therapy. Researchers analyzed blood and tumor tissue samples before and after treatment. The goal was…

This study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…

This study looked at how Hirschsprung disease, a rare birth defect affecting the bowel, impacts brain development and quality of life in children aged 8 to 13. Researchers tested thinking skills and surveyed families to understand long-term effects after surgery. The goal was to …

This study looked at whether a food safety training program helps food service employees improve their knowledge, attitudes, and practices around safe food handling. About 200 adult workers took part, and the training covered personal hygiene and safe food preparation. The goal w…

This study tested whether a family history app can help doctors collect and use information about patients' family health risks. Over 600 adults aged 30-69 took part. The goal was to see if the app leads to better screening and genetic referrals for conditions like cancer, heart …

This completed study involved 116 people with advanced melanoma. Researchers aimed to create a platform that goes beyond standard genetic testing to deeply profile tumors using advanced molecular technologies. The goal was to discover new biomarkers and help doctors make better t…

This study tested a school program called SocLaLola that uses a comic book to teach children aged 8-11 about pain. The goal was to see if it improves kids' understanding of pain and reduces their fear of moving. Eighty-two students from two primary schools took part. The program …

This completed study brought together men who have had suicidal thoughts to help design suicide prevention tools. Over up to 10 meetings, 13 men gave feedback on tool drafts, focusing on usability, privacy, and support. The goal was to create resources that truly fit their needs.

This study involved 60 people with advanced melanoma who were already scheduled to receive immunotherapy drugs. Researchers collected blood samples and, when possible, tumor samples before and during treatment to look for biological markers that might predict whether the treatmen…

This completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…

This completed study tested whether giving families of children with long-term illnesses (like cancer, heart disease, or premature birth) a tablet computer with a special app helps them manage care at home. Researchers measured satisfaction, cost-effectiveness, and how well famil…

This study examined blood and tumor samples from 25 people with advanced melanoma who were starting standard pembrolizumab treatment. Researchers looked at T cells—key immune cells—to find patterns that might predict whether the therapy works. The goal is to better understand why…

This study looked at 22 people with advanced (Stage IV) melanoma to see if DNA floating in their blood could show genetic changes in their cancer before and after chemotherapy. Researchers compared the DNA found in blood samples with the original tumor's genetics. The goal was to…

This study looked at the DNA changes (mutations) in eye cancers called ocular melanoma. Researchers analyzed tumor samples from 58 patients to understand how these cancers develop and spread. The goal was to identify key mutations that could lead to better treatments in the futur…

This study looked at 68 people with a rare type of skin cancer called mucosal melanoma. Researchers used a special PET scan to see if certain imaging details could predict how long patients live or when their cancer might come back. The goal is to help doctors make better treatme…

This study looked at whether people with advanced cancers (melanoma, kidney, or lung cancer) receiving their first immunotherapy treatment could successfully collect small blood samples at home using a finger-prick method. The goal was to see if this approach is practical and rel…

This study looked at 14 adults with melanoma who were taking a combination of BRAF and MEK inhibitor drugs. The goal was to understand how these drugs can affect the retina, the light-sensitive part of the eye. Researchers used eye exams and special imaging to track changes over …

This study looked at immune cells (T cells, NK cells, and macrophages) inside melanoma tumors from 217 patients. The goal was to understand how these cells affect the body's ability to fight the cancer and how chemotherapy might change them. It was an observational study, not a t…

This completed study looked at 132 people with advanced melanoma to see if levels of a protein called interferon-gamma (IFN-γ) in their tumors or blood could predict how well they would respond to first-line immunotherapy drugs like pembrolizumab, nivolumab, or a combination. The…

This study tested whether removing a wound dressing just 6 hours after facial skin surgery is better than keeping it covered for 7 days. 144 adults with benign skin lesions like moles or cysts were randomly assigned to one of the two methods. Researchers checked for swelling, red…

This study examined 30 people with melanoma who were taking BRAF/MEK inhibitor drugs to see how often these drugs cause retinal changes (MEKAR) and what those changes look like. Participants had regular eye exams before, during, and after treatment. The goal was to better underst…

This completed study created a French national registry for people with rare overgrowth syndromes caused by PIK3CA gene mutations. Researchers collected medical and genetic information from 28 patients to better understand these conditions and estimate how many people are affecte…

This study tested whether an artificial intelligence (AI) tool could help primary care doctors more accurately diagnose skin conditions and decide which patients need to see a skin specialist. 131 adults with various skin issues, including possible skin cancer, took part. Doctors…

This study looked at how a genetic test that checks 25 genes linked to hereditary cancers is used in clinics. Over 1,500 people with a personal or family history of cancer took part. Researchers collected blood samples and had participants fill out questionnaires over five years …

This study created a new imaging-based grading system to help doctors predict how complex and risky surgery will be for patients with rare adrenal and nerve tumors called PPGL. Researchers used 3D scans from 500 patients to develop the system, aiming to improve surgical planning …

This study followed 187 melanoma patients treated with IMLYGIC, a modified herpes virus that attacks cancer cells. Researchers tracked whether the virus spread to patients' close contacts or healthcare providers, and monitored long-term safety for up to 5 years. The goal was to u…

This completed study collected blood and tumor tissue from 64 patients with advanced cancers (like melanoma, breast, lung, and kidney cancer) to study genetic changes and treatment resistance. The samples are stored for future research, including genomic analysis. No new treatmen…

This study looked at 173 Chinese patients to see if their skin type (based on the Baumann Skin Type system) affects how well they heal and scar after facial surgery for benign growths like moles or cysts. Researchers checked wound healing at 7 days and scar quality at 90 days usi…

This completed study tracked 132 children with obstructive sleep apnea who had their tonsils removed. Researchers recorded how many had breathing problems after surgery, especially those with other health issues. The goal was to create a simple flowchart to help doctors decide wh…

This small pilot study tested whether special PET scans (FLT PET/CT) could detect early signs that immunotherapy is working in people with advanced melanoma. Five participants received standard immunotherapy drugs (pembrolizumab or nivolumab) and had scans, blood tests, and tumor…

This completed trial tested an interactive survivorship program for adolescent and young adult cancer survivors. The program included a mobile app, telehealth support, and printed materials to help survivors access healthcare resources, improve self-management skills, and reduce …

This study looked at whether a simple blood sample can detect genetic mutations in patients with advanced melanoma. Currently, doctors need to take a piece of the tumor (biopsy) to check for key gene changes that guide treatment. The goal was to see if circulating tumor DNA in th…

This study looked at whether a patient's abdominal circumference (belly size) is linked to how long surgery takes to remove a pheochromocytoma, a rare adrenal tumor. Researchers reviewed records of 159 adults who had the surgery. The goal was to see if belly size could help docto…

This completed study tested whether an interactive website could help 485 melanoma survivors do better at protecting their skin from the sun and checking their skin for new or returning cancers. Participants used the website and reported how often they used sunscreen, wore protec…

This study tested a mobile health tool called CAARE to help children under 12 and their caregivers cope with emotional and behavioral challenges after a traumatic injury. Researchers measured changes in distress, PTSD symptoms, depression, and quality of life in 54 participants. …

This study followed about 400 adults with advanced BRAF-mutant melanoma who were taking targeted therapy (BRAF/MEK inhibitors) and using a smartphone app called TavieSkin. The goal was to describe patient characteristics, how they used the app, their quality of life, and treatmen…

This completed study looked at 1,200 people with neurocutaneous syndromes (NF1, TSC, SWS, VHL) in Western China. Researchers compared those who received genetic testing, targeted drugs, and coordinated specialist care against those who got standard care. The goal was to see if pr…

This completed study from Memorial Sloan Kettering Cancer Center looked at how people with a close family member who had melanoma make decisions about sun protection. Researchers interviewed 94 participants and used an electronic diary to track daily behaviors like sunscreen use …

This study looked at 98 adults with cancers like melanoma and lung cancer who were starting immunotherapy. Researchers measured inflammatory markers in their blood to understand how the body reacts to these drugs. The goal was to find ways to better manage side effects from treat…

This study reviewed medical records of 12 children with CHARGE syndrome who had cochlear implant surgery. Researchers looked at their ear bone structure and surgical challenges to find ways to make the operation safer. The goal is to help surgeons better prepare for the unique an…

This study looked at whether giving a written sheet to melanoma patients, to pass on to their close relatives, helps those relatives get a skin exam from a doctor. 420 patients and their family members took part. The goal was to see if the written reminder works better than just …

This study tested a new blood test (liquid biopsy) to find cancer markers in 135 people with head and neck, lung, or skin cancer. The goal was to see if the blood test works as well as a standard tissue biopsy. The study did not provide treatment but aimed to improve how doctors …

This study looked back at the medical records of 232 adults with advanced melanoma to find out which factors—like patient traits, tumor features, and treatments—are linked to better outcomes. Researchers reviewed data from people treated between 2022 and 2024 at hospitals in Türk…

This study looked at how children with Noonan syndrome process energy and sugar. Researchers measured insulin sensitivity in 20 children with the condition to see if they have unique metabolic traits. The goal was to better understand the disease, not to test a new treatment.

This study looked at how well the combination of dabrafenib and trametinib works in real-life settings for people with high-risk stage III melanoma that has been completely removed by surgery. It included 39 adults in Turkey whose melanoma had a specific genetic mutation (V600E).…

This study looked at people with advanced solid tumors (like lung, bladder, or melanoma) who had been on immunotherapy for one year and whose disease was stable. Half stopped treatment and half continued. The goal was to see if stopping early affected how long until the cancer pr…

This study looked at whether a special training program could help primary care doctors better spot and treat early-stage skin cancer, especially melanoma. Fifty-four doctors from two clinics took part. The training aimed to improve their knowledge and skills in identifying suspi…

This study measured how children with and without autism look at faces, body movements, and objects using eye-tracking technology. Researchers wanted to see if visual patterns could help understand social differences in autism. 150 children took part, including those with autism …

This completed study at Stanford University looked at the DNA of over 1,000 adults with Neurofibromatosis Type 1 (NF1) to find genetic differences that might explain why some people develop more skin neurofibromas than others. Participants provided blood or saliva samples for gen…

This study looked at 73 people with many moles to see if certain mole features can help predict who is most likely to develop melanoma. Participants gave saliva samples and had their moles photographed and analyzed. The goal is to improve risk assessment and make melanoma screeni…

This study looked at 119 children who had platinum-based chemotherapy for certain cancers. Researchers wanted to find out if certain genes make some kids more likely to develop hearing loss from the treatment. By analyzing DNA from saliva samples, they hope to identify high-risk …

This study aimed to develop a blood test that can detect tiny bits of tumor DNA in patients with metastatic choroidal melanoma, a rare eye cancer that has spread. Researchers tested blood samples from 40 adults to see if the test could reliably find cancer DNA. The goal was to cr…

This completed study examined whether healthy skin near a melanoma tumor contains hidden cancer stem cells that might predict the disease's return. Researchers analyzed tissue from 226 people with early-stage melanoma to see if these cells are linked to 5-year survival. The goal …

This study compared two blood test methods, EPISPOT and CellSearch, to see how well they detect circulating melanoma cells in people with advanced melanoma. Researchers took blood samples from 73 participants, including patients with stage 4 melanoma and hospitalized controls wit…

This completed study looked at 100 adults with stage III melanoma that could be removed by surgery. Researchers compared two immunotherapy drug combinations given before surgery: nivolumab plus relatlimab versus nivolumab plus ipilimumab. The goal was to understand patient charac…

This study tested whether analyzing the DNA and RNA of a child's tumor could help doctors choose personalized treatments. It included 186 children with relapsed or hard-to-treat cancers like neuroblastoma and brain tumors. The goal was to see if this approach was feasible and saf…

This study measured levels of the laxative PEG 3350 and its breakdown products in the blood and urine of 158 children who were already taking it, compared to children not taking it. The goal was simply to learn how the body processes this medicine, not to change any treatments. R…

This study looked at 631 advanced melanoma patients treated with immune checkpoint inhibitors. Researchers wanted to see if the time until a patient needs their next treatment or dies (TNT-D) is a good stand-in for overall survival. The goal was to find a quicker way to measure h…

This early-phase trial tested a special PET/CT imaging agent, Zirconium Zr 89 Crefmirlimab Berdoxam, to see if it can measure immune activity in tumors of patients with advanced melanoma. Six adults on immunotherapy plus hydroxychloroquine received scans before and after starting…

This study aimed to create a communication tool to help doctors and patients discuss when cancer stops responding to treatment. Researchers interviewed 128 people, including patients with certain breast cancers, metastatic uveal melanoma, parents of children with cancer, and heal…

This study looked at whether measuring tumor DNA in the blood can help doctors know if surgery to remove liver metastases from uveal melanoma was successful. Researchers took blood samples from 60 patients before and after surgery and during follow-up. The goal was to see if chan…

This study tracked immune cell changes in 5 people with advanced melanoma who were taking nivolumab with or without ipilimumab. Researchers took blood and skin samples at several time points to compare immune responses between those who responded to treatment and those who did no…

This study looked at 32 people with advanced melanoma who were treated with the immunotherapy drug Nivolumab. Researchers took blood samples before and during treatment to track changes in immune cells. The goal was to find differences between patients whose tumors shrank or stay…

This completed study looked at how the pigment layer of the eye works in 30 people with neurofibromatosis type 1. Researchers used special eye tests to measure electrical signals from the pigment layer and compared them to images of the back of the eye. The goal was to confirm ea…

This study tested a method to identify immune cells (T cells) that recognize unique mutations in tumors. Researchers took blood and lymph node samples from 25 patients with breast cancer or melanoma. The goal was to see if they could find and measure these cancer-specific immune …